Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea

Dyslipidemia Clinical Trial

— CRESENDO  

Official title:

Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01372956
• Other study ID #: NIS-CKR-XXX-2011/1
• Status: Completed
• Phase: N/A
• First received: June 7, 2011
• Last updated: December 21, 2011
• Start date: August 2011
• Est. completion date: October 2011

Study information

• Verified date: December 2011
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Korea Food and Drug Administration (KFDA)
• Study type: Observational

Clinical Trial Summary

This is a multi-centre, cross-sectional, chart review study to investigate cholesterol goal attainment rates defined by modified NCEP-ATP III guidelines and define its possible determinants among Korean dyslipidemic patients

Description:

MC MD

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4950
• Est. completion date: October 2011
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Patient who has a dyslipidemia with a lipid profile result within 3 months

• Patient who has a dyslipidemia without change of lipid lowering drug dosage during 3 months after lipid profile test.

Exclusion Criteria:

• Patient who involved in this study previously.

• Patient who participated in other clinical study with study drug within 90 days.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias

Locations

Country	Name	City	State
Korea, Republic of	Research Site	Anyang	Gyeonggi-do
Korea, Republic of	Research Site	Bucheon	Gyeonggi-do
Korea, Republic of	Research Site	Bundang	Gyeonggi-do
Korea, Republic of	Research Site	Busan	Kyeongsangnam-do
Korea, Republic of	Research Site	Busan
Korea, Republic of	Research Site	Changwon	Kyeongsangnam-do
Korea, Republic of	Research Site	Cheonan	Chungcheongnam-do
Korea, Republic of	Research Site	Cheongju	Chungcheongbuk-do
Korea, Republic of	Research Site	Chuncheon	Kangwon-do
Korea, Republic of	Research Site	Daegu	Kyeongsangbuk-do
Korea, Republic of	Research Site	Deagu	Kyeongsangbuk-do
Korea, Republic of	Research Site	Goyang	Gyeonggi-do
Korea, Republic of	Research Site	Guri	Gyeonggi-do
Korea, Republic of	Research Site	Gwangju	Jeollabuk-do
Korea, Republic of	Research Site	Gwangju
Korea, Republic of	Research Site	Iksan	Jeollabuk-do
Korea, Republic of	Research Site	Incheon
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Tae	Chungcheongnam-do
Korea, Republic of	Research Site	Uijeongbu	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cholesterol goal attainment rate according to NCEP-ATP III guideline		Once, at enrollment	No
Secondary	Factors for cholesterol goal achievement: Age, Family history, smoking history, waist circumstance, etc.		Once, at enrollment	No
Secondary	Cholesterol goal attainment rate related to CHD or disease history		Once, at enrollment	No